Study of immune markers in multisystem inflammatory syndrome in children (MIS-C)
- Conditions
- Health Condition 1: U071- COVID 19 virus identified
- Registration Number
- CTRI/2021/12/039054
- Lead Sponsor
- Indian Council of Medical Research
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 100
Study group:
Patients diagnosed to be MIS-C cases by the treating physicians and co-investigators at the three collaborating centres (Kasturba Medical College, Manipal; Kasturba Medical College, Mangalore and Ramaiah Medical College, Bangalore) as per the WHO case definition.
Control groups:
There will be three sub-groups in this:
A) SARS-CoV-2 RT PCR positive patients in the age group, 0 – 19, not fitting into the WHO case definition of MIS-C.
B) Age matched healthy controls who are negative for SARS-CoV-2 RT-PCR and do not have signs and symptoms of any ongoing infection.
C) Children were classified as having complete/incomplete Kawasaki Disease (KD) by using American Heart Association criteria
Subjects on immunomodulatory therapy for samples obtained following the first visit to the treating physician
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Plasma cytokines, sC5b-9 and anti SARS-CoV-2 IgG and neutralizing antibody levels along with clinical correlation may help diagnose and differentiate MIS-C from other conditions with overlapping clinical features like Kawasaki disease.Timepoint: At first visit and follow up after 1 month
- Secondary Outcome Measures
Name Time Method nderstand the pathophysiology of MIS-CTimepoint: At first visit and follow up after 1 month